Update on the safety profile of certolizumab pegol in rheumatoid arthritis: An integrated analysis from clinical trials Review uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Arthritis, Rheumatoid
  • Immunoglobulin Fab Fragments
  • Immunosuppressive Agents
  • Polyethylene Glycols

abstract

  • No new or unexpected safety signals associated with CZP emerged in this updated long-term safety analysis. While SIE rates were higher for CZP than for placebo in RCT, the rate decreased with continued exposure to CZP. These rates are consistent with data previously reported for CZP and other tumour necrosis factor inhibitors.

publication date

  • January 2015

Research

keywords

  • Review

Identity

Language

  • eng

PubMed Central ID

  • PMC4283674

Digital Object Identifier (DOI)

  • 10.1136/annrheumdis-2013-203660

PubMed ID

  • 24092417

Additional Document Info

start page

  • 96

end page

  • 103

volume

  • 74

number

  • 1